Belite Bio 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Belite Bio reported 3rd quarter 2026 R&D expenses of $15.5 million, compared to $10.3 million in 2025; non-GAAP R&D expenses, excluding share-based compensation expenses, were $14.7 million, compared to $8 million in 2025.
- Q3 SG&A expenses were $21.4 million, compared to $12.7 million in 2025; non-GAAP SG&A expenses were $16.3 million, compared to $2.1 million in 2025.
- GAAP net loss in the 3rd quarter was $30.3 million, compared to $21.7 million in 2025; non-GAAP net loss, excluding share-based compensation, was $24.3 million, compared to $8.8 million in 2025.
- Belite Bio ended the quarter with $774 million in cash, cash equivalents, and US Treasury bills, compared to $780 million in Q2 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio third quarter 2026 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please raise your hand. If you have dialed in to today's call, please press star nine to raise your hand and star six to unmute. I will now hand the conference over to Julie Fallon. Please go ahead. Good afternoon.
Thank you for joining us today. On the call are Dr. Tom Lin, Chairman and CEO of Belite Bio, Dr. Hendrik Scholl, Chief Medical Officer, Dr. Nathan Mata, Chief Scientific Officer, and Hao-Yuan Chuang, Chief Financial Officer. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today we will be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. Now I'll turn the call over to Dr. Lin.
Dr. Lin? Thank you, Julie.
Good afternoon, everyone. Thank you for joining our third quarter 2026 financial results and corporate update call. This has been a transformative year for Belite Bio, and we are rapidly progressing on the regulatory front as we work to bring tinlarebant to patients. We were very excited to report in August that the FDA accepted our NDA for tinlarebant with priority review and a PDUFA date of February 12, 2027. The FDA has also informed us that it will not convene an advisory committee meeting to discuss the NDA for tinlarebant in Stargardt disease. Since our U.S. NDA submission, we have also submitted a JNDA in Japan under Sakigake designation for accelerated review. If approved, this will be the first Sakigake pharmaceutical product for ophthalmology disease in Japan.
We have also submitted a marketing authorization application to the regulatory authorities in the U.K., Switzerland, and Singapore via the Access Consortium framework. While we will be thoughtful and measured in our international rollout strategy, these regulatory submissions are an important step toward a goal of making tinlarebant available to Stargardt patients worldwide. On another note, we have recently announced that our stock has been uplisted from the Nasdaq Capital Market to the Nasdaq Global Select Market. This is the highest of the three Nasdaq market tiers. The uplisting reflects the company's compliance with the Nasdaq Global Select Market's more stringent financial and liquidity standards, as well as our continued progress in strengthening our financial profile and capital market presence. We are very proud of this achievement as we look to continually drive value for shareholders.
As we make progress on the regulatory front, we are also continuing to build on our commercial plans and working to ensure optimal patient access to tinlarebant by engaging early with payers and pharmacy benefit managers. We have already begun forging these important relationships to help us support broad coverage following potential approval. We look forward to providing further updates as we come down to our PDUFA date, and I am confident in our ability to execute a quick launch and to rapidly begin bringing this medicine to patients. I will now turn the presentation over to Hao-Yuan to discuss the financials.
Hao? Thank you, Tom. We have had a strong year so far and have executed well financially as we prepare for our first potential product launch.
Let me recap our financial statements. For the third quarter of 2026, our R&D expenses were $15.5 million compared to $10.3 million in 2025. The increase in R&D expenses in the quarter was primarily attributable to the increase in API manufacturing and DP manufacturing expenses, consulting fees, and sponsorship fundings. On a non-GAAP basis, excluding share-based compensation expenses, R&D expenses in the third quarter was $14.7 million compared to $8 million in 2025. SG&A expenses in Q3 were $21.4 million compared to $12.7 million in 2025. The increase in SG&A expenses in the quarter was primarily attributable to an increase in professional service fee. On a non-GAAP basis, SG&A expenses for the third quarter was $16.3 million compared to $2.1 million in 2025.
GAAP net loss in the third quarter was $30.3 million compared to $21.7 million in 2025. On a non-GAAP basis, excluding share-based compensation, we reported a non-GAAP net loss of $24.3 million for the third quarter compared to $8.8 million in 2025. We ended the quarter with $774 million in cash equivalents, and US Treasury bills, compared to $780 million in Q2 2026. Overall, our balance sheet remains strong, and we are extremely well-funded. Looking ahead, we believe our current cash runway is sufficient to support the potential commercialization of tinlarebant, subject to regulatory approval, and to continue advancing our pipelines. With that, I will now turn the call back to the operator for Q&A.
Operator? Thank you. We will now begin the question-and-answer session.
If you would like to ask a question, please raise your hand now. If you have dialed into today's call, please press star nine to raise your hand and star six to unmute. Please stand by as we compile the Q&A roster. Your first question comes from the line of Maxwell Skor with Morgan Stanley. Your line is open. Please go ahead.
Great. Thank you very much for taking my question. Since PHOENIX enrolled patients with smaller lesions, how do you think about earlier intervention as a way to stand out in the GA market?
Thanks. Thank you. Thanks, Maxwell.
Hendrik, I think you are the best person to answer this.
Yeah, I'm happy to take that question. The inclusion criteria of our PHOENIX trial include a range of lesion sizes that would also cover smaller lesions. If we find specifically positive effect on smaller lesions, that would become obvious when the trial results are available. It is correct that targeting bisretinoid accumulation in the RPE could indeed be something that preserves RPE and photoreceptors early on, and could indeed have a very positive treatment effect in earlier disease stages, while geographic atrophy is already a late disease stage of AMD.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
